The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2024

Filed:

Oct. 22, 2019
Applicant:

Iomx Therapeutics Ag, Martinsried, DE;

Inventors:

Peter Sennhenn, Martinsried, DE;

Sebastian Meier-Ewert, Martinsried, DE;

Nisit Khandelwal, Martinsried, DE;

David Bancroft, Martinsried, DE;

Assignee:

IOMX THERAPEUTICS AG, Planegg/Martinsried, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 417/14 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61P 35/00 (2018.01);
Abstract

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.


Find Patent Forward Citations

Sennhenn, Peter. (2024). Heterocyclic kinase inhibitors and uses thereof (U.S. Patent No. 12172993). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12172993

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…